ALPHARETTA, Ga.--(BUSINESS WIRE)--
Believes a Reconstituted Board is Immediately Needed to Reverse Strategic, Operational and Oversight Failures at the Company
Urges Stockholders to Continue to Make their Voices Heard Following 2019 Annual Meeting
Believes Recently-Announced Lantheus Transaction Massively Undervalues the Company and is a Desperate Attempt by Current Leadership to Avoid Accountability at all Costs
Velan’s Nominees Possess the Relevant Skill Sets and Experience to Help Unlock the Value of Progenics and Ensure the Proper Evaluation of All Options to Maximize Stockholder Value
Velan to Issue Comprehensive Plan Outlining How Progenics Can Reach its Potential
Vote on the GREEN Consent Card TODAY to Save Progenics
Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has sent a letter to fellow Progenics stockholders and filed a definitive consent statement with the Securities and Exchange Commission in connection with its solicitation of written consents from stockholders to reconstitute the Progenics Board of Directors through the removal of the three long-tenured directors and the election of five new, highly-qualified, fully-independent nominees.
The full text of Velan’s letter is available at the following link: https://savepgnx.com/api/v1/files/1cd2427f-6d35-42c2-b822-08d74bcac849
CERTAIN INFORMATION CONCERNING PARTICIPANTS
Velan Capital, L.P., Altiva Management Inc., Balaji Venkataraman, Virinder Nohria, LTE Partners, LLC, LTE Management, LLC, Melkonian Capital Management, LLC, Ryan Melkonian, Terence Cooke, Deepak Sarpangal, Gérard Ber, Eric J. Ende, Ann MacDougall, Heinz Mäusli and David W. Mims (collectively, the “Participants”) have filed a definitive consent statement and accompanying GREEN consent card with the Securities and Exchange Commission (“SEC”) to be used to solicit consents from stockholders of Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for a number of proposals, the ultimate effect of which, if successful, would be to reconstitute the Board of Directors of the Company (the “Board”) through the removal of three current members of the Board and the election of the Participants’ five director nominees.
Stockholders are advised to read the definitive consent statement and any other documents related to the solicitation of consents by the Participants because they contain important information, including additional information relating to the Participants. These materials and other materials filed by the Participants in connection with the solicitation of consents will be available at no charge at the SEC’s website at www.sec.gov. The definitive consent statement and other relevant documents filed by the Participants with the SEC will also be available, without charge, by calling the Participant’s proxy solicitor, Okapi Partners LLC, toll-free at (888) 785-6673 or by requesting copies via email to firstname.lastname@example.org.